226 related articles for article (PubMed ID: 10874215)
21. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
22. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody.
Zhang M; Sakahara H; Yao Z; Saga T; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1997 Jan; 24(1):61-4. PubMed ID: 9080476
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
Lu QJ; Bian GX; Chen YY; Zhang M; Guo SM; Wen LQ
Acta Pharmacol Sin; 2005 Oct; 26(10):1259-64. PubMed ID: 16174444
[TBL] [Abstract][Full Text] [Related]
24. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
26. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.
Kobayashi H; Sun BF; Yoo TM; Le N; Kim MK; Paik CH; Pastan I; Waldmann TA; Carrasquillo JA
J Nucl Med; 1999 Aug; 40(8):1381-91. PubMed ID: 10450692
[TBL] [Abstract][Full Text] [Related]
27. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
29. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
30. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
Frost SH; Bäck T; Chouin N; Jensen H; Hultborn R; Jacobsson L; Lindegren S
Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
[TBL] [Abstract][Full Text] [Related]
31. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases.
Mahteme H; Lövqvist A; Graf W; Lundqvist H; Carlsson J; Sundin A
Anticancer Res; 1998; 18(2A):843-8. PubMed ID: 9615730
[TBL] [Abstract][Full Text] [Related]
33. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
34. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.
Koppe MJ; Soede AC; Pels W; Oyen WJ; Goldenberg DM; Bleichrodt RP; Boerman OC
Int J Cancer; 2003 Oct; 106(6):965-72. PubMed ID: 12918078
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
36. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
[TBL] [Abstract][Full Text] [Related]
39. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.
Garambois V; Glaussel F; Foulquier E; Ychou M; Pugnière M; Luo RX; Bezabeh B; Pèlegrin A
BMC Cancer; 2004 Oct; 4():75. PubMed ID: 15488142
[TBL] [Abstract][Full Text] [Related]
40. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
